Acrivon is developing best-in-class targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon’s unprecedented patient selection method represents a paradigm change in precision oncology drug development. Powered by our AP3 platform, we match drug mechanisms to the biologic drivers of cancer in patients, uncovering drug sensitivity not achievable through genomics.
Accelerated precision oncology
Committed to delivering real therapeutic outcomes for patients
Aiming to address the world’s most common and pressing cancers, Acrivon’s technology and pipeline is built to improve patient outcomes.
This is possible due to our unique OncoSignature® patient selection test, which is designed to accurately match our therapeutics with patients to ensure they will truly benefit from our treatments.
Our pipelineOur pipeline is initially focused on DNA Damage Response, cell cycle, and transcriptional regulators.
Our lead program, ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, second-generation kinase inhibitor of the DNA Damage Response. Currently in phase 2 clinical development, ACR-368 has demonstrated durable single agent activity, including complete responses, in a proportion of patients and a favorable safety profile across multiple high unmet need solid cancer types.
Our two preclinical, internally-developed pipeline programs target critical nodes involved in the replication stress response and cell cycle regulation.
Partnering with AcrivonImpactful therapeutics matched to the right patients
Our AP3 platform uniquely enables Acrivon to develop in-licensed, internally developed, and partnered therapeutics in patient selection trials for accelerated approval pathway. We continually assess in-licensing and partnering opportunities with like-minded visionary companies.